EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research-Reference-Cited by-同舟云学术

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research

Published:2021-05 Issue: Volume:167 Page:105583
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Dong Rui-Fang,Zhu Miao-Lin,Liu Ming-Ming,Xu Yi-Ting,Yuan Liu-Liu,Bian Jing,Xia Yuan-Zheng,Kong Ling-Yi

Funder

Ministry of Education of the People's Republic of China

China Pharmaceutical University State Key Laboratory Of Natural Medicines

Ministry of Science and Technology of the People's Republic of China

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference184 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA: Cancer J. Clin.,2021

2. Cancer treatment and survivorship statistics,2019;Miller;CA Cancer J. Clin.,2019

3. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N. Engl. J. Med.,2009

4. Overview of current systemic management of EGFR-mutant NSCLC;Hsu;Ann. Oncol.,2018

5. Mechanisms of resistance to egfr tyrosine kinase inhibitors and therapeutic approaches: an update;Ahsan;Adv. Exp. Med. Biol.,2016

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Schisandrin C inhibits AKT1-regulated cell proliferation in A549 cells;International Immunopharmacology;2024-12

2. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer;European Journal of Medicinal Chemistry;2024-11

3. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

4. Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review;Frontiers in Oncology;2024-08-09

5. Cancer-associated fibroblasts mediate resistance to anti-EGFR therapies in cancer;Pharmacological Research;2024-08